Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (13.6), the stock would be worth ¥11.65 (28% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19 | ¥16.28 |
0%
|
| 3-Year Average | 13.6 | ¥11.65 |
-28%
|
| 5-Year Average | 16.9 | ¥14.55 |
-11%
|
| Industry Average | 30.7 | ¥26.36 |
+62%
|
| Country Average | 28.8 | ¥24.73 |
+52%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
|
17.2B CNY | 19 | 10 326.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 159 | 44.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.2 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 39.6 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 19.6 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 25.1 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 45.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 21.9 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 11.7 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Shandong Buchang Pharmaceuticals Co Ltd
Glance View
Shandong Buchang Pharmaceuticals Co Ltd, a stalwart in China's pharmaceutical industry, was founded with a traditional focus but a modern vision. The company thrives on its deep expertise in developing and manufacturing traditional Chinese medicine (TCM) products, capitalizing on the rich tapestry of Eastern medicinal practices. Its extensive portfolio spans cardiovascular, cerebrovascular, and neurological disorders, areas highly pertinent to China’s aging population. By seamlessly integrating modern scientific techniques with age-old herbal wisdom, Buchang positions itself uniquely in a market that appreciates both tradition and innovation. This dual focus allows the company to tap into the growing demand for health solutions that marry efficacy with cultural familiarity. Financially, Buchang Pharmaceuticals' revenue is primarily fueled by its established healthcare products, which are marketed extensively across China’s vast healthcare network. The company shrewdly invests in building dedicated sales channels, leveraging a combination of direct engagement with healthcare professionals and strategic partnerships with medical institutions. Their emphasis on R&D ensures a steady pipeline of products, aiming to break into new therapeutic areas and expand its market presence. Buchang’s strategy to blend traditional remedies with modern delivery forms not only bolsters its domestic sales but also paves the way for potential international expansion, as global interest in holistic and alternative health solutions continues to grow. This sophisticated operational model underscores Buchang's ability to adapt and prosper amid shifting healthcare paradigms.